molecules of the month

Merck PCSK9 Inhibitors

macrocyclic PCSK9/LDLR PPI inhibitor

oral PD in Ph. I with MK-0616

from mRNA display screen and SBDD

published example: compound 44

Merck & Co.

Merck oral PCSK9 inhibitor macrocycle chemical structure drug hunter molecules of the year
2 mins read

MK-0616 is a macrocyclic PCSK9 inhibitor with demonstrated once-daily PCSK9-lowering and LDL-cholesterol-lowering activities in a human clinical trial (<300 mg QD). Currently PCSK9-targeting therapies are only available by injection, and the cost-benefit of using large molecules to lower cholesterol has been hotly debated. Identification of oral PCSK9 inhibitors has been something of a “holy grail” for the field, but difficult to achieve due to the poor ligandability of the target. While MK-0616 has not been formally published, related macrocycles have been disclosed that illustrate the concept. The Merck bicyclic macrocyclic peptide PCSK9 inhibitor, “compound 44,” is a highly potent (Ki = 0.00239 nM) and orally bioavailable (cyno %F = 2.9, t1/2 = 10 h) agent that demonstrated in vivo  target…

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: